References
- Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298: 1912–34.
- Prudent R, Cochet C. New protein kinase CK2 inhibitors: jumping out of the catalytic box. Chem Biol 2009;16:112–20.
- Niefind K, Guerra B, Ermakowa I, Issinger OG. Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J 2001;20:5320–31.
- Burnett G, Kennedy EP. The enzymatic phosphorylation of proteins. J Biol Chem 1954;211:969–80.
- Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003;17:349–68.
- Smith EM, Lin JM, Meissner RA, Allada R. Dominant-negative CK2alpha induces potent effects on circadian rhythmicity. PLoS Genet 2008;4:e12.
- Maier B, Wendt S, Vanselow JT, Wallach T, Reischl S, Oehmke S, et al. A large-scale functional RNAi screen reveals a role for CK2 in the mammalian circadian clock. Genes Dev 2009;23:708–18.
- Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI, et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007;13:1019–28.
- Stalter G, Siemer S, Becht E, Ziegler M, Remberger K, Issinger OG. Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochem Biophys Res Commun 1994;202:141–7.
- Daya-Makin M, Sanghera JS, Mogentale TL, Lipp M, Parchomchuk J, Hogg JC, et al. Activation of a tumor-associated protein kinase (p40TAK) and casein kinase 2 in human squamous cell carcinomas and adenocarcinomas of the lung. Cancer Res 1994;54:2262–8.
- Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, Ahmed K. Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate 1994;24:11–16.
- Pallares J, Llobet D, Santacana M, Eritja N, Velasco A, Cuevas D, et al. CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. Am J Pathol 2009;174: 287–96.
- Guerra B, Issinger OG. Protein kinase CK2 in human diseases. Curr Med Chem 2008;15:1870–86.
- Seldin DC, Leder P. Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 1995;267:894–7.
- Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD, Sonenshein GE, et al. Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem 2001;227: 153–65.
- Perera Y, Farina HG, Hernández I, Mendoza O, Serrano JM, Reyes O, et al. Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int J Cancer 2008;122:57–62.
- Nie Z, Perretta C, Erickson P, Margosiak S, Lu J, Averill A, et al. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a][1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Bioorg Med Chem Lett 2008;18:619–23.
- Ma H, Deacon S, Horiuchi K. The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov 2008;3:607–21.
- Förster T. Zwischenmolekulare Energiewanderung und Fluoreszenz. Ann Phys 1948;6:55–75.
- Weimer S, Oertel K, Fuchsbauer HL. A quenched fluorescent dipeptide for assaying dispase- and thermolysin-like proteases. Anal Biochem 2006;352:110–19.
- Naughton MA, Sanger F. Purification and specificity of pancreatic elastase. Biochem J 1961;78:156–63.
- Narayanan AS, Anwar RA. The specificity of purified porcine pancreatic elastase. Biochem J 1969;114:11–17.
- Kuenzel EA, Mulligan JA, Sommercorn J, Krebs EG. Substrate specificity determinants for casein kinase II as deduced from studies with synthetic peptides. J Biol Chem 1987;262:9136–40.
- Beythien J, White PD. A solid phase linker strategy for the direct synthesis of EDANS-labelled peptide substrates. Tetrahedron Lett 2005;46:101–4.
- Grankowski N, Boldyreff B, Issinger OG. Isolation and characterization of recombinant human casein kinase II subunits alpha and beta from bacteria. Eur J Biochem 1991;198:25–30.
- Guerra B, Götz C, Wagner P, Montenarh M, Issinger OG. The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation. Oncogene 1997;14:2683–8.
- Rodems SM, Hamman BD, Lin C, Zhao J, Shah S, Heidary D, et al. A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol 2002;1:9–19.
- Meggio F, Pagano MA, Moro S, Zagotto G, Ruzzene M, Sarno S, et al. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry 2004;43:12931–6.